Welcome to MOLOGEN AG

Our research - for you. That means, we conduct research to develop highly effective drugs with few side effects and excellent tolerability. Our main focus is on oncology and severe infectious diseases.

We use latest expertise from the fields of molecular medicine and immunology to enable the human immune system to fight the disease or disease pathogen itself - an approach that we are promoting with great conviction.

Using our own, patent-protected technology platforms, we are able to produce highly effective and extremely well-tolerated drugs against diseases with high unmet medical need. 

Biotechnology company MOLOGEN AG made progress in the first quarter of 2015 with regard to patient recruitment for its current clinical trials with the MGN1703 immunotherapy, which is the company’s main product candidate. MOLOGEN’s quarterly report, published today, stated a slight decrease in research and development (R&D) expenses. In... [more]

MOLOGEN AG (ISIN DE0006637200/WKN 663720) successfully placed new shares from the cash capital increase resolved on 24 March 2015 with indirect subscription rights of the existing shareholders and subsequent international private placement with qualified investors in the full amount of 5,657,875 shares (corresponds to 33.33 % of the currently... [more]

Interim Report 1st Quarter 2015

Download PDF (0,4 MB)

Annual Report 2014

Download PDF (0,4 MB)

Capital Increase 2015

Please click here for further information.